TY - JOUR
T1 - Understanding the use of NIV in ALS
T2 - results of an international ALS specialist survey
AU - Heiman-Patterson, Terry D.
AU - Cudkowicz, Merit E.
AU - De Carvalho, Mamede
AU - Genge, Angela
AU - Hardiman, Orla
AU - Jackson, Carlayne E.
AU - Lechtzin, Noah
AU - Mitsumoto, Hiroshi
AU - Silani, Vincenzo
AU - Andrews, Jinsy A.
AU - Chen, Dafeng
AU - Kulke, Sarah
AU - Rudnicki, Stacy A.
AU - van den Berg, Leonard H.
N1 - Publisher Copyright:
© 2018, © 2018 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.
PY - 2018/7/3
Y1 - 2018/7/3
N2 - Objective: To identify common practices of noninvasive ventilation (NIV) use among ALS specialists and how they follow respiratory status in their patients. Methods: A 25-item questionnaire on NIV indications/initiation was sent via SurveyMonkey® to ALS specialists identified through membership in NEALS (114 sites in the US) and ENCALS (39 sites in Europe). Descriptive statistics and Cochran–Mantel–Haenszel test for general association were performed. Results: In their initial evaluation, US and European specialists (n = 186) use upright forced vital capacity (FVC) most (92.8% vs 91.1%; p = 0.752). Upright FVC results are most important for US respondents when deciding to prescribe NIV; European respondents consider symptoms of orthopnea and/or dyspnea as most important. European respondents use overnight pulse oximetry (69.8% vs 7.9%; p < 0.001) and arterial blood gas analyses (62.8% vs 3.2%; p < 0.001) more than US respondents. Insurance regulations/national health care coverage impact NIV initiation more in the US than in Europe (70.0% vs 47.5%; p = 0.025). When asked if insurance/other financial constraints affects when they prescribe NIV, more US respondents answered positively (77.2% vs 15.4%; p < 0.001). In patients with no respiratory symptoms, most US specialists (68.3%) initiated NIV at VC <50% predicted; European responses showed greater variability. Conclusions: Given the impact of NIV on respiratory function and the importance of respiratory function to quality of life and survival, understanding differences that influence NIV prescribing is critical. This information may inform future study design and identify areas warranting additional research to develop best practices for NIV implementation.
AB - Objective: To identify common practices of noninvasive ventilation (NIV) use among ALS specialists and how they follow respiratory status in their patients. Methods: A 25-item questionnaire on NIV indications/initiation was sent via SurveyMonkey® to ALS specialists identified through membership in NEALS (114 sites in the US) and ENCALS (39 sites in Europe). Descriptive statistics and Cochran–Mantel–Haenszel test for general association were performed. Results: In their initial evaluation, US and European specialists (n = 186) use upright forced vital capacity (FVC) most (92.8% vs 91.1%; p = 0.752). Upright FVC results are most important for US respondents when deciding to prescribe NIV; European respondents consider symptoms of orthopnea and/or dyspnea as most important. European respondents use overnight pulse oximetry (69.8% vs 7.9%; p < 0.001) and arterial blood gas analyses (62.8% vs 3.2%; p < 0.001) more than US respondents. Insurance regulations/national health care coverage impact NIV initiation more in the US than in Europe (70.0% vs 47.5%; p = 0.025). When asked if insurance/other financial constraints affects when they prescribe NIV, more US respondents answered positively (77.2% vs 15.4%; p < 0.001). In patients with no respiratory symptoms, most US specialists (68.3%) initiated NIV at VC <50% predicted; European responses showed greater variability. Conclusions: Given the impact of NIV on respiratory function and the importance of respiratory function to quality of life and survival, understanding differences that influence NIV prescribing is critical. This information may inform future study design and identify areas warranting additional research to develop best practices for NIV implementation.
KW - Amyotrophic lateral sclerosis
KW - noninvasive ventilation
KW - respiratory function
KW - vital capacity
UR - http://www.scopus.com/inward/record.url?scp=85045438804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045438804&partnerID=8YFLogxK
U2 - 10.1080/21678421.2018.1457058
DO - 10.1080/21678421.2018.1457058
M3 - Article
C2 - 29661084
AN - SCOPUS:85045438804
SN - 2167-8421
VL - 19
SP - 331
EP - 341
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - 5-6
ER -